DENVER, Colorado — August 27, 2025 — Leads & Copy — LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) co-sponsored an international conference on activating oncogenic signaling as a cancer treatment strategy. The meeting, also co-organized by Professor Rene Bernards, a LIXTE board member, showcased data indicating LIXTE’s compound LB-100 can activate oncogenic signaling, proving toxic to cancer cells.
Traditional cancer therapies inhibit oncogenic pathways, but this conference explored activating these pathways to push cancer cells beyond survival limits. LB-100, a PP2A inhibitor, exemplifies this approach by triggering uncontrolled signaling activity in cancer cells, leading to self-destruction and generating neoantigens that make tumors more visible to immune attack.
Presentations at the conference reinforced the recognition of PP2A inhibition, demonstrating that LB-100 induces hyperactivation of growth pathways, leading to cancer cell toxicity and creating synergy with immunotherapy. LIXTE’s co-sponsorship of the meeting underscores its leadership in advancing innovative therapeutic strategies.
LIXTE Biotechnology Holdings, Inc. is focused on developing cancer therapies targeting the PP2A pathway. Its lead compound, LB-100, is a PP2A inhibitor with preclinical results and early-stage clinical tolerability. LIXTE is advancing a trial in Ovarian Clear Cell Carcinoma.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Source: LIXTE Biotechnology Holdings, Inc.
